← 治験一覧に戻る
日本におけるCOVID-19予防のためのAZD1222の研究
基本情報
- NCT ID
- NCT04568031
- ステータス
- 完了
- 試験のフェーズ
- 第1/第2相
- 試験タイプ
- 介入
- 目標被験者数
- 256
- 治験依頼者名
- AstraZeneca
概要
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no licensed preventions available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID 19 prevention would have significant global public health impact.
対象疾患
COVID-19
介入
AZD1222(DRUG)
0.9% (w/v) saline(DRUG)
依頼者（Sponsor）
IQVIA(INDUSTRY)
アストラゼネカ株式会社(INDUSTRY)